Know Cancer

or
forgot password

Prostate Cancer Education in African American Men


Phase 2/Phase 3
45 Years
70 Years
Not Enrolling
Male
Prostate Cancer Screening Decision

Thank you

Trial Information

Prostate Cancer Education in African American Men


African American and African-Caribbean men have the greatest prostate cancer incidence and
mortality rate. Professional organizations provide conflicting recommendations regarding
prostate cancer testing but generally agree that men learn about the risks and benefits of
testing and share in decisions about testing based on their personal preferences. This study
was designed to assess the effects of a decision support intervention on men's knowledge
about prostate cancer testing, participation in medical decisions about testing, decision
conflict related to testing, and the congruence between prostate cancer testing intentions
and behaviors. A randomized controlled trial was conducted. Participants were randomized
into one of two conditions: (a) tailored telephone education about prostate cancer testing
(intervention group) or (b) tailored telephone education about national guidelines for fruit
and vegetable consumption (attention control group).


Inclusion Criteria:



- 45 to 70 year old

- African descent

- accessible by telephone

- have primary care physician

Exclusion Criteria:

- Prostate cancer test in 12 months prior to enrollment

- History of prostate cancer

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening

Outcome Measure:

congruence between prostate cancer testing intention and behavior

Outcome Description:

Congruence between men's stated intentions to get tested and their actual testing behavior, validated by medical claims at 1 and 2 year follow-up. Intention-behavior agreement was coded as congruent (1), whereas disagreement was coded as incongruent (0).

Outcome Time Frame:

1 and 2 years post randomization

Safety Issue:

No

Principal Investigator

Stephen Lepore, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Temple University

Authority:

United States: Institutional Review Board

Study ID:

R01CA104223

NCT ID:

NCT01415375

Start Date:

September 2004

Completion Date:

July 2009

Related Keywords:

  • Prostate Cancer Screening Decision
  • prostate-specific antigen (146-154)
  • prostate-specific antigen (154-163)
  • Prostatic Neoplasms

Name

Location

Temple University Philadelphia, Pennsylvania  19140